Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PEN
HoldFallen FavouritePenumbra, Inc. · Healthcare · United States · $12.7B · Avg Vol: $86M/d
COMPANY DESCRIPTION
Penumbra, Inc. designs, develops, manufactures, and markets innovative medical devices for neurovascular and peripheral vascular diseases. The company is a niche market leader in advanced interventional therapies, particularly for stroke and vascular embolization, driven by a strong R&D pipeline. Penumbra focuses on highly specialized, minimally invasive technologies that significantly improve patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 847.1M | 1.1B | 1.2B | 1.4B | 18.3% | 1.5B | 1.6B | 1.8B | 13.2% |
| EPS | -0.05 | 2.37 | 0.36 | 4.57 | 38.9% | 4.08 | 5.70 | 7.30 | 26.4% |
| Shares | 38.1M | 38.7M | 38.5M | 39.2M | +2.9% | 39.4M | — | — | — |
| Debt | 235.8M | 234.3M | 223.4M | 219.7M | -2.3% | 212.7M | — | — | — |
| Equity | 998.9M | 1.2B | 1.2B | 1.4B | 12.6% | — | — | — | — |
| Op CF | -55.7M | 97.3M | 168.5M | 238.7M | 56.6% | 277.8M | — | — | — |
| Inv CF | 54.8M | -16.1M | 77.6M | -404.6M | — | — | — | — | — |
| Fin CF | 11.6M | 16.2M | -87.0M | 26.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PEN | Penumbra, Inc.(you) | $12.7B | 51 | Hold |
| PODD | Insulet Corporation | $10.1B | 48 | Hold |
| GKOS | Glaukos Corporation | $10.6B | 46 | Hold |
| BRKR | Bruker Corporation | $8.7B | 47 | Hold |
| BIO | Bio-Rad Laboratories, Inc. | $10.4B | 70 | Buy |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| BSX | Boston Scientific Corporation | $67.9B | 48 | Hold |
| STE | STERIS plc | $22.8B | 76 | Buy |
| AXGN | Axogen, Inc. | $2.8B | 57 | Hold |
| NEOG | Neogen Corporation | $2.5B | 46 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%